

Erratum

Mineralocorticoid receptor blockade—a novel approach to fight hyperkalaemia in chronic kidney disease

Eberhard Ritz¹ and Bertram Pitt²

¹Nierenzentrum, University of Heidelberg, Heidelberg, Germany and ²Internal Medicine and Cardiovascular Disease, University of Michigan Medical School, Ann Arbor, MI, USA

Correspondence and offprint requests to: E. Ritz; E-mail: prof.e.ritz@t-online.de, bueroritz@gmx.de

Clin Kidney J (2013); 6:464–468. doi:10.1093/ckj/sft084

This article was originally published with an incorrect conflict of interest statement. The correct conflict of interest should be as follows:

B Pitt has received consulting fees from: Relypsa, Amorce, Aurasence, Bayer, BG-Medicine, Cytopherx, Gambro, Lilly, Mesoblast, Novartis, Pfizer, scTherapeutics, Sticares, InterACT

and Takeda; stock options from Relypsa, Aurasence, BG-Medicine and scTherapeutics; and travel support from Relypsa, Bayer, Gambro Mesoblast and Pfizer. E. Ritz has no conflict of interest.

The author apologises for this error.